胰高血糖素样肽-1受体激动剂暴露与眼压变化之间的关联:GLP-1受体激动剂与眼压变化
这项回顾性临床队列研究基于加州大学健康数据仓库,纳入使用GLP-1受体激动剂或 other 口服降糖药的患者,比较暴露前后眼压变化。GLP-1受体激动剂组平均眼压变化为-0.4±2.8 mmHg(配对t检验P<.001),其他口服降糖药组为-0.2±3.3 mmHg(配对t检验P=.297);多变量GEE中仅暴露前眼压是眼压变化的独立预测因素。
要点
- GLP-1受体激动剂组平均眼压变化为-0.4±2.8 mmHg(配对t检验P<.001)。
- 其他口服降糖药组平均眼压变化为-0.2±3.3 mmHg(配对t检验P=.297)。
- 多变量GEE中仅暴露前眼压是眼压变化的独立预测因素。
核心结论
- 配对分析中GLP-1受体激动剂与眼压降低显著相关,但多变量GEE中与眼压变化无关,且两组眼压变化差异小。
研究设计与样本
- 回顾性临床队列研究,查询加州大学健康数据仓库。
- 纳入使用GLP-1受体激动剂的患者626例共1247只未接受青光眼手术或治疗的眼,以及使用其他口服降糖药的患者547例共1083只未接受青光眼手术或治疗的眼。
- 索引日期定义为首次暴露于药物的日期,纳入在索引日期365天内至少有一次暴露前和一次暴露后眼压记录的眼。
- 暴露于青光眼降眼压药物或接受青光眼手术的眼被排除。
- 主要结局指标为暴露后眼压变化,采用配对t检验和广义估计方程(GEE)分析。
主要发现
- 中位年龄66.2岁[IQR=18.3],女性607例(51.7%),白人667例(56.9%)。
- 暴露前中位眼压15.2 mmHg[IQR=3.8],中位血红蛋白A1c 7.5[IQR=2.4],中位体重指数29.8[IQR=9.4]。
- 776例(66.1%)患有糖尿病,中位活性口服降糖药数量为1.0[IQR=1.0],441例(37.5%)为胰岛素使用者。
- 两组间若干暴露前特征存在差异。
- GLP-1受体激动剂组平均眼压变化为-0.4±2.8 mmHg(配对t检验P<.001),其他口服降糖药组为-0.2±3.3 mmHg(配对t检验P=.297)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study evaluates the effects of glucagon-like peptide-1 receptor (GLP-1R) agonists on intraocular pressure (IOP). DESIGN: Retrospective clinical cohort study. METHODS: The University of California Health Data Warehouse was queried for patients exposed to GLP-1R agonists or other oral antidiabetics. A total of 1247 glaucoma surgery and treatment naïve eyes of 626 patientson GLP-1R agonists and 1083 glaucoma surgery and treatment naïve eyes of 547 patients on other oral antidiabetics were included. Index date was defined as the date of first exposure to the medication. Eyes with at least one pre-exposure and one post-exposure tonometry records within 365 days of the index date were included. Clinical and laboratory data were extracted. Eyes were excluded upon exposure to glaucoma hypotensive medication or glaucoma surgery. The primary outcome measure was ∆IOP after exposure, which was analyzed using a paired t test and generalized estimating equations (GEE) RESULTS: The median age was 66.2 years [IQR = 18.3]; 607 (51.7%) were female, and 667 (56.9%) were Caucasian. Median pre-exposure IOP, hemoglobin A1c, and body mass index were 15.2 mm Hg [IQR = 3.8], 7.5 [IQR = 2.4], and 29.8 [IQR = 9.4], respectively. A total of 776 individuals (66.1%) had diabetes, with the median number of active oral antidiabetics being 1.0 [IQR = 1.0], and 441 (37.5%) being insulin users. Several pre-exposure characteristics differed between the groups. The mean ∆IOP was -0.4 ± 2.8 mm Hg (paired t test P < .001) and -0.2 ± 3.3 mm Hg (paired t test P = .297) in the GLP-1R agonist and other antidiabetics groups, respectively. Pre-exposure IOP was the only independent predictor of ΔIOP in multivariable GEE. Sensitivity analyses yielded similar results. CONCLUSIONS: Although GLP-1R agonists were significantly associated with a decrease in IOP in the paired analysis, they were not associated with ΔIOP in multivariable GEE. Moreover, the difference in ΔIOP between the two groups was small.
引用
- Hallaj S, Halfpenny W, Chuter BG, et al. Association Between Glucagon-Like Peptide-1 Receptor Agonists Exposure and Intraocular Pressure Change: GLP-1 Receptor Agonists and Intraocular Pressure Change. Am J Ophthalmol. 2024. PMID: 39237049. doi:10.1016/j.ajo.2024.08.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。